Strides Shasun gets USFDA nod for Oseltamivir Phosphate capsules

Image
Press Trust of India New Delhi
Last Updated : Jun 11 2018 | 8:50 PM IST

Drug firm Strides Shasun today said its subsidiary Strides Pharma Global Pte has received final approval from the US Food and Drug Administration (USFDA) for generic Oseltamivir Phosphate capsules.

The company has received approval from the US health regulator for the capsules in the strengths of 30 mg (base), 45 mg (base) and 75 mg (base), Strides Shasun said in a BSE filing.

The product is a generic version of Hoffmann-La Roche Inc's Tamiflu capsules, it added.

"As per IQVIA MAT April 2018 data, the US market for Oseltamivir Phosphate Capsules was approximately USD 725 million," Strides Shasun said.

The product will be manufactured at the company's oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market, it added.

Oseltamivir Phosphate capsule is prescribed to treat symptoms caused by the flu virus.

Shares of Strides Shasun today closed at Rs 349.65 apiece on BSE, down 2.25 per cent from its previous close.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 11 2018 | 8:50 PM IST

Next Story